Bone Mineral Markers in Hypogonadism

Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism

The aim of this study is to investigate the markers of bone mineral metabolism in an unconfounded group of patients with hypogonadism and to search for a relationship between endothelial dysfunction and insulin resistance.

Cardiometabolic disorders are prevalent in patients with hypogonadism. Endothelial dysfunction and insulin resistance are used in determining cardiovascular risk. The role of markers of bone mineral metabolism in hypogonadism is not clearly presented.

49 male patients with hypogonadotropic hypogonadism (HH) and 43 BMI and age matched healthy male subjects were enrolled. Osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-23), vitamin D and asymmetric dimethylarginine (ADMA) levels were measured. The insulin sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR) formula.

Inclusion Criteria:

• male patients with hypogonadotropic hypogonadism
• being under the age of 45 and over the age of 18
• not previously given testosterone or human chorionic gonadotropin therapy
• not have any chronic metabolic disorders or organ dysfunction

Exclusion Criteria:

• female patients
• Other reasons hipogondism
• receive any treatment of hypogonadism
• presence of comorbid diseases